Mar 5, 2026 07:30AM

Jan 14, 2026 10:39AM

Jan 5, 2026 04:31AM

Dec 22, 2025 07:06AM

Dec 3, 2025 03:16AM

May 8, 2025 08:00AM

Apr 1, 2025 07:01AM Compass Therapeutics, Inc (CMPX) Reports CTX-009 Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study

Apr 1, 2025 07:00AM

Nov 12, 2024 08:00AM

Sep 16, 2024 06:49AM

Aug 12, 2024 08:00AM

May 13, 2024 08:00AM

Apr 25, 2024 08:00AM

Apr 16, 2024 08:00AM Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

Mar 21, 2024 09:00AM

Feb 28, 2024 08:00AM

Jan 5, 2024 08:03AM

Jan 5, 2024 08:00AM

Nov 9, 2023 07:30AM

Jun 22, 2023 04:07PM

Nov 9, 2022 04:10PM UPDATE: Compass Therapeutics (CMPX) PT Raised to $8 at Raymond James

Nov 9, 2022 09:00AM

Jul 18, 2022 07:05AM

May 16, 2022 08:00AM

May 9, 2022 08:00AM

Mar 21, 2022 08:02AM

Mar 21, 2022 08:00AM

Jan 20, 2022 08:37AM Compass Therapeutics (CMPX) Announces FDA Clearance of IND for Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 and Vascular Endothelial Growth Factor A

Jan 20, 2022 08:30AM

Nov 12, 2021 08:30AM

Nov 1, 2021 04:03PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All